Drug Database
AN

anti-H5N1 avian influenza antibodies (Fabenflu / FBF001)

✓ Approved

Fab'entech · Polyclonal Antibodies · Polyclonal Antibodies

What is anti-H5N1 avian influenza antibodies?

anti-H5N1 avian influenza antibodies is a polyclonal antibodies developed by Fab'entech. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesFabenflu, FBF001
CompanyFab'entech
Drug ClassPolyclonal Antibodies, Antibody
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Fab'entech

Therapeutic Indications

anti-H5N1 avian influenza antibodies is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsInfluenza✓ Approved

Related Research Articles

PubMedVeterinary microbiology2026-07-25

Optimization of filters and processing conditions for aerosol detection of relevant avian respiratory viruses in poultry under experimental and field conditions.

Trenado Claudia C, Cea-Callejo Pablo P, Gomez-Lucia Esperanza E, Novoa Samuel S et al.

Airborne transmission contributes substantially to the spread of avian respiratory viruses, yet standardized and field-validated air sampling methods remain limited. Although significant efforts focus on improving the detection of avian influenza virus on farms, the rapid identification of other prevalent avian respiratory viruses is essential. This study systematically assessed the performance of cellulose-based, polytetrafluoroethylene (PTFE), and gelatin filters for capturing and recovering avian metapneumovirus (aMPV), infectious bronchitis virus (IBV), infectious laryngotracheitis virus (ILTV), and Newcastle disease virus (NDV). Laboratory assays using viral dilutions spiked onto filter surfaces were conducted to optimize elution conditions and to compare viral titer losses across different filter types. PTFE and gelatin filters consistently achieved the highest viral recovery rates in laboratory conditions and were subsequently field-tested in a commercial breeding hen farm. Under these conditions, using both impactor-based air samplers and passive sampling, the optimized PTFE and gelatin filters enabled early detection of low-pathogenicity IBV strains in environmental samples, even in the absence of clinical signs. This demonstrates the sensitivity of the approach for identifying low-level viral circulation. Individual hen sampling and qPCR assays confirmed the presence of IBV GI-12 and IBV G1-13 in cloacal swabs, while inoculation of embryonated eggs demonstrated viable virus in a subset of cloacal samples. Collectively, these findings demonstrate that appropriate filter selection and sample processing protocols are essential for reliable environmental viral detection. They support implementing air sampling as a practical component of routine surveillance and biosecurity programs against prevalent avian respiratory viruses beyond influenza.

PMID 42497499
Read full article →
PubMedThe American journal of medicine2026-07-25

Advances in Cancer Immunotherapy.

Esnaola Gabriela R GR, Goetzl Edward J EJ

Individual cancer specificity, high level of effectiveness for hematopoietic malignancies and modest side-effects have elevated immune approaches to first-line treatment of many cancers. Monoclonal anti-tumor cytotoxic antibodies, chemotherapeutic agents bound to anti-tumor antibodies, antibodies to immune checkpoint inhibitors and chimeric antigen receptor (CAR)-T cells are established useful elements of cancer immunotherapy. It has recently been shown that patients receiving healthy donor encapsulated fecal microbiota before immune checkpoint inhibitor therapy have better responses and fewer severe side-effects. Newly designed constructs of CAR-T or -NK cells with a different second CAR, capacity to produce antibodies to immune checkpoint inhibitors or inducers of IL-12 or IL-15 generation are recent major advances especially for immunotherapy of solid tumors. Gene-edited B cell/plasma cell clones that produce tumor cell cytotoxic antibodies in vivo and vaccination with tumor-specific neoantigens or mRNAs encoding tumor-specific neoantigens in combination with antibodies to immune checkpoint inhibitors are also meaningful recent advances.

PMID 42498103
Read full article →
PubMedInfluenza and other respiratory viruses2026-07-25

Contribution of E190D and Q226H Mutations in HA to the Receptor-Binding Profile of D1.1 Genotype H5N1 Viruses.

Fang Yang Y, Yang Lei L, Zou Shumei S, Liu Liqi L et al.

A 2024 human HPAI H5N1 case in British Columbia showed mixed viral populations containing HA-190D (28%) and HA-226H (35%) variants in tracheal aspirate sequencing. In this study, solid-phase binding assay and molecular docking were used to evaluate the contribution of HA-E190D/Q226H mutations to the viral receptor profiles. Our results showed that HA-E190D marginally reduced sialic acid α2,3 receptors' affinity, while HA-Q226H impaired both sialic acid α2,3 and α2,6 receptors' binding. These results demonstrate that neither mutation strengthens viral binding to human-type receptors, indicating that such substitutions are unlikely to heighten the public health threat posed by the virus for now.

PMID 42498495
Read full article →
PubMedAnnals of pediatric cardiology2026-07-25

Fetal atrial flutter in the setting of immune-mediated complete atrioventricular block: A unique combination of fetal arrhythmias.

Rakha Shaimaa S, Alahmadi Fadwa F

Fetal exposure to maternal anti-Ro/SSA antibodies can result in several cardiac disorders, most commonly atrioventricular block (AVB). Immune-mediated complete AVB is typically an irreversible complication of maternal anti-Ro antibodies and could result in intrauterine fetal demise. Atrial arrhythmias are rarely reported in patients with maternal anti-Ro/SSA autoantibodies. This report presents a rare combination of fetal arrhythmias, with transient episodes of fetal atrial flutter superimposed on a complete AVB rhythm. No antiarrhythmic medication was required. However, the adverse outcome associated with advanced AVB was unavoidable.

PMID 42499824
Read full article →
PubMedEBioMedicine2026-07-25

An experimentally validated structure-based computational framework for humanisation of anti-orthopoxvirus antibodies.

Yang Xuehua X, Dong Xuemeng X, Lu Jiahan J, Chi Xiaojing X et al.

The re-emergence of orthopoxviruses, most notably mpox virus (MPXV), poses a growing global public health threat. Well-characterised murine anti-orthopoxvirus antibodies are clinically limited by anti-mouse antibody responses, while traditional sequence-based humanisation often impairs antigen-binding activity. We developed an experimentally validated structure-guided computational humanisation framework prioritising 3D architectural congruence over sequence identity, integrating Foldseek-based structural alignment and interface-residue constraints. We applied this framework to humanise two murine anti-orthopoxvirus antibodies (7D11, A27D7), with comprehensive in vitro and in vivo validation. Structural superimposition confirmed high conformational conservation between the humanised variants (POX1.1 and POX2.1) and their parental mAbs, with root mean square deviation (RMSD) values below 0.6 Å for all variable domains. Both humanised variants retained full epitope specificity with natural humanness profiles. POX1.1 showed enhanced neutralisation potency against vaccinia virus (VACV) and MPXV, compared with the parental 7D11. POX2.1 preserved the broad cross-reactive binding and the extracellular enveloped virion neutralising activity of the parental A27D7. In the lethal VACV mouse model, both monotherapies conferred significant prophylactic and therapeutic protection, reducing pulmonary viral loads and improving survival. The dual-targeting combination of POX1.1 and POX2.1 achieved markedly improved in vivo efficacy compared with individual antibodies, delivering 100% survival even when administered 2 days post-challenge. In the MPXV CAST/EiJ mouse model, the combination significantly reduced splenomegaly and MPXV DNA loads in plasma, spleen and lung tissues, effectively suppressing systemic viral dissemination. These findings establish that the structure-centric workflow enables efficient humanisation of well-characterised murine anti-orthopoxvirus antibodies, providing a validated framework to support the development of countermeasures for orthopoxvirus pandemic. This work was supported by the National Natural Science Foundation of China, the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, the Scientific Research Innovation Capability Support Project for Young Faculty and the National Science and Technology Major Project.

PMID 42497650
Read full article →
PubMedBiomaterials science2026-07-25

A dual-tumor-recognition trispecific T-cell nano-engager enhances effector-target conjugation and antitumor activity.

Ma Ya-Jing YJ, Zhang Zheng Z, Kang Jian-Kang JK, Che Xiu-Hai XH et al.

T-cell engagers redirect cytotoxic lymphocytes toward malignant cells, but their efficacy in solid tumors is limited by uneven antigen expression and inefficient effector-target contact. Here, we report a modular dual-tumor-recognition trispecific T-cell nano-engager (Tri-NanoTCE) generated by Fc-mediated assembly of anti-PD-L1, anti-EGFR, and anti-CD3 IgG1 antibodies on an FcγR1-HSA/PLLA nano-adaptor. PD-L1 and EGFR provide complementary tumor recognition and anchoring, whereas CD3 recruits T cells. Tri-NanoTCE retained the binding activity of all antibodies, showed efficient antibody loading, and increased tumor-cell surface association relative to single-target nano-engagers. This dual-recognition design strengthened effector-target conjugation, enhanced CD69 expression, cytotoxic mediator release, and PBMC-mediated tumor-cell killing, and outperformed free antibody mixtures or dual-component controls. In PBMC-reconstituted MDA-MB-231 and A375 xenografts, Tri-NanoTCE prolonged intratumoral retention, increased human T-cell infiltration, and suppressed tumor growth without obvious short-term systemic toxicity. These findings support modular nanoassembly as a materials strategy for constructing trispecific T-cell engagers for antigen-heterogeneous solid tumors, particularly where target coverage and effector contact are limiting.

PMID 42498266
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about anti-H5N1 avian influenza antibodies